Biocon launches denosumab biosimilars in US market
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Biocon Ltd. (BION)
The Biocon share price today is 381.85, view NSE BION stock exchange data. Track the latest Biocon share price with real-time updates on BION stock performance including market cap, day range, 52-week range and dividend yield. Access BION charts, earnings dates and analyst estimates to support your investment decisions.
383.35
+2.75(+0.72%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
379.60
386.30
52 wk Range
317.90
424.95
Earnings results expected today
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
379.60386.30
52 wk Range
317.90424.95
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.14%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.14%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
BION Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
416.53
Upside
+8.65%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Prominent player in the Biotechnology industry
- Biocon receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Biocon receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Biocon launches denosumab biosimilars in US market
- Investing.com
- Biocon receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Biocon receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
12 Buy
2 Hold
5 Sell
Ratings:
19 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 416.53
(+8.65% Upside)
Earnings
Latest Release
12-02-2026
EPS / Forecast
0.95 / 1.14
Revenue / Forecast
41.73B / 45.2B
Compare BION to Peers and Sector
Metrics to compare | BION | Peers Peers - average of corresponding metrics from companies closely matching BION: SYNGENE, WOCKPHARMA, MANKIND, A068270, AUROPHARMA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBIONPeersSector |
|---|---|---|---|---|
P/E Ratio | 101.9x | 35.1x | −0.5x | |
PEG Ratio | −3.51 | 0.32 | 0.00 | |
Price/Book | 2.3x | 3.6x | 2.6x | |
Price / LTM Sales | 3.7x | 4.1x | 3.2x | |
Upside (Analyst Target) | 11.5% | 5.0% | 48.3% | |
Fair Value Upside | Unlock | 2.7% | 5.6% | Unlock |
Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services, and other research and development in the fields of pharmaceuticals, drug discovery, biotechnology pharmaceuticals, and medicinal sciences, etc.; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Biocon (BION) Share Price Today?
The Biocon share price today is 383.35.
What is the current Biocon (BION) share price and day range?
As of 07-05-2026, the Biocon share price is 383.35, with a previous close of 380.60. The share price has ranged from 379.60 to 386.30 today, while the 52-week range spans from 317.90 to 424.95.
What Is the Biocon Market Cap?
As of today, Biocon market cap is 617.25B.
Does Biocon Pay Dividends? What's The Current Dividend Yield?
The Biocon dividend yield is 0.14%.
What Is the Biocon (BION) Share Price Target?
The average 12-month share price target for Biocon is 416.53, with a high estimate of 580 and a low estimate of 290. 12 analysts recommend buying, while 5 suggest selling, with an overall rating of Buy and +8.65% Upside potential.
What Is Biocon's Earnings Per Share (TTM)?
The Biocon EPS (TTM) is 4.76.
When Is the Next Biocon Earnings Date?
Biocon will release its next earnings report on 07-05-2026.
From a Technical Analysis Perspective, Is BION a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Biocon Trade On?
Biocon is listed and trades on the India National Stock Exchange.
What Is the Stock Symbol for Biocon?
The stock symbol for Biocon is "BION."
How Many Times Has Biocon Stock Split?
Biocon has split 3 times.
How Many Employees Does Biocon Have?
Biocon has 16420 employees.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.